Table 4. Adverse cardiac events in the three study groups (31).
Cardiac event | Total (n=703) | Troponin −/− (n=495) | Troponin +/− (n=145) | Troponin +/+ (n=63) |
---|---|---|---|---|
Sudden death | 3 (0.4%) | 0 (0%) | 0 (0%) | 3 (4.8%) |
Cardiac death | 2 (0.3%) | 0 (0%) | 0 (0%) | 2 (3.2%) |
Acute pulmonary edema | 3 (0.4%) | 0 (0%) | 1 (0.7%) | 2 (3.2%) |
Heart failure | 47 (6.7%) | 1 (0.2%) | 18 (12.4%) | 28 (44.4%) |
Asymptomatic left ventricular dysfunction | 37 (5.3%) | 2 (0.4%) | 24 (16.6%) | 11 (17.5%) |
Life-threatening arrhythmias | 17 (2.4%) | 2 (0.4%) | 10 (6.9%) | 5 (7.9%) |
Conduction disturbances requiring pacemaker implantation | 2 (0.3%) | 0 (0%) | 0 (0%) | 2 (3.2%) |
Cumulative events | 111 (15.8%) | 5 (1.0%) | 53 (36.6%)* | 53 (84.1%)** |
*, P<0.001 vs. Troponin I −/− group; **, P<0.001 vs. Troponin I +/− group.